Matching donor to recipient in lung transplantation: How much does size matter?  by Mason, David P. et al.
T
XMatching donor to recipient in lung transplantation: How much does
size matter?
David P. Mason, MD,a Lillian H. Batizy, MS,b Jeffrey Wu, MD,a Edward R. Nowicki, MD, MS,a Sudish C. Murthy, MD, PhD,a
Ann M. McNeill, RN,a Marie M. Budev, DO,c Atul C. Mehta, MD,c Go¨sta B. Pettersson, MD, PhD,a and
Eugene H. Blackstone, MDa,b
Objective: The impact of size matching between donor and recipient is unclear in lung transplantation. Therefore,
we determined the relation of donor lung size to 1) posttransplant survival and 2) pulmonary function as measured
by forced expiratory volume in 1 second.
Methods: From 1990 to 2006, 469 adults underwent lung transplantation with lungs from donors aged 7 to 70
years. Donor and recipient total lung capacities were calculated using established formulae (predicted total lung
capacity), and actual recipient lung size was measured in the pulmonary function laboratory. Disparity between
donor and recipient lung size was expressed as a ratio of donor predicted total lung capacity to recipient predicted
total lung capacity—the predicted total lung capacity ratio—and predicted donor total lung capacity to actual re-
cipient total lung capacity—the actual total lung capacity ratio. Survival was measured by multiphase hazard
methodology and repeated measures of National Health and Nutrition Examination Survey–normalized forced
expiratory volume in 1 second analyzed by temporal decomposition.
Results: Predicted total lung capacity ratio and actual total lung capacity ratio ranged widely, from 0.55 to 1.59
and 0.52 to 4.20, respectively. Overall survival was unaffected by predicted total lung capacity ratio (P ¼ .3) or
actual total lung capacity ratio (P¼ .5). Patients with emphysema and an actual total lung capacity ratio of 0.67 or
less or 1.03 or greater had higher predicted mortality (P ¼ .01). During the first posttransplant year, forced ex-
piratory volume in 1 second increased and then gradually declined. Predicted total lung capacity ratio and actual
total lung capacity ratio had a small impact on forced expiratory volume in 1 second, primarily in the late phase
after transplant in a disease-specific manner.
Conclusion: Size matching between donor and recipient using predicted total lung capacity ratio and actual total
lung capacity ratio is an effective technique. Wide discrepancies in lung sizing do not affect overall posttransplant
survival or pulmonary function. Therefore, a greater degree of lung size mismatch can likely be accepted, thereby
improving patients’ odds of undergoing transplantation.
CARDIOTHORACIC TRANSPLANTATIONSupplemental material is available online.
Transplant surgeons carefully evaluate donor lung size to op-
timize matching to a prospective recipient.1-4 However, there
is no consensus on the definition of best ‘‘size fit’’ or how to
achieve it.5 Some surgeons size match using donor and recip-
ient height values while taking into account recipient disease
diagnosis.6-8 Our program and other transplant programs cal-
culate donor and recipient total lung capacity (TLC) values
and attempt to achieve as close a size match as possible.
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(pTLC) and actual TLC (aTLC), which can vary widely
depending on the underlying diagnosis.4 To establish an op-
timal sizing strategy, we compared the ratio of donor-to-
recipient TLC and evaluated its relation to 1) survival after
lung transplantation and 2) postoperative spirometry values.
PATIENTS AND METHODS
Patients
From February 1990 to December 2006, 469 patients aged 18 years or
older underwent primary lung transplantation for end-stage lung disease
at Cleveland Clinic, exclusive of heart–lung transplantation. Recipient, do-
nor, and surgical data were extracted from the Unified Transplant Database,
which has been approved for use in research by the institutional review
board, with patient consent waived. Results of spirometry performed in
the Cleveland Clinic’s certified pulmonary function laboratory, which
conforms to American Thoracic Society standards, were retrieved from
the Pulmonary Function Test database.9 The institutional review board ap-
proved supplemental review of medical records, also with patient consent
waived. The mean age of patients at transplant was 48  12 years (range
18–71 years), and 51% were men (Table 1).
Total Lung Capacity
aTLC is measured by plethysmography and affected by underlying
pulmonary disease, whereas pTLC is calculated using a formula thatrgery c May 2009
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XAbbreviations and Acronyms
aTLC ¼ actual total lung capacity
aTLCR ¼ recipient actual total lung capacity
aTLCRatio ¼ donor-to-recipient actual total lung
capacity ratio
FEV1% ¼ forced expiratory volume in 1 second
IPF ¼ idiopathic pulmonary fibrosis
pTLC ¼ predicted total lung capacity
pTLCD ¼ donor predicted total lung capacity
pTLCRatio ¼ donor-to-recipient predicted total lung
capacity ratio
TLC ¼ total lung capacity
incorporates age, gender, height, and weight.10,11 Formulas believed to be
most accurate for pTLC were used in this analysis (Appendix A). aTLC
of potential recipients was available in 309 patients (66%). It was not fea-
sible to measure aTLC in donors.
Patients with emphysema (a-1 antitrypsin deficiency and chronic ob-
structive pulmonary disease) had a larger aTLC than pTLC, with idiopathic
pulmonary fibrosis (IPF) smaller than predicted; for bronchiectasis and cys-
tic fibrosis, these values were similar (Figure 1). In addition, pTLCRatio was
calculated by dividing donor pTLC (pTLCD) by recipient pTLC (pTLCR) to
evaluate matching to predicted lung size. Similarly, TLCRatio was calculated
by dividing pTLCD by recipient aTLC (aTLCR) to evaluate matching to ac-
tual lung size.
Donor pTLC ranged from 2.37 to 8.56 L, median 5.49 L (15th and 85th
percentiles 4.73–7.38), and recipient pTLC ranged from 3.49 to 8.69 L, me-
dian 5.75 L (15th and 85th percentiles 4.73–7.07). pTLCRatio ranged from
0.55 to 1.59, median 1.0 (15th and 85th percentiles 0.87–1.13). There was
only small variation across disease diagnoses (Table 2; Figure 2, A).
aTLCRatio ranged from 0.52 to 4.20, median 0.96 (15th and 85th percentiles
0.71–1.84). There was considerable variation of aTLCRatio across recipient
diagnoses, with emphysema having the smallest aTLCRatio and IPF having
the largest, and bronchiectasis again falling in between (Table 2, Figure 2, B).
End Points
The 3 primary end points were 1) overall and 2) disease-specific survival
and 3) National Health and Nutrition Examination Survey–normalized post-
operative forced expiratory volume in 1 second (FEV1%).12 Postoperative
spirometry became available electronically in 1994. Thus, among 382 of
469 patients (81%), 7673 FEV1% values were retrieved. Median postoper-
ative data collection time was 16 months from transplant (range 3 days to 15
years; Figure E1). These data were considered reliable for estimating tem-
poral pattern of FEV1% to at least 6 years.
Follow-up
Anniversary follow-up as of April 24, 2007, was used for the analyses.
Fourteen patients (3%) were transferred at various times to outside institu-
tions and lost to follow-up. All patients had at least 1 year of follow-up, with
1605 patient-years of data available for analysis. Median follow-up among
survivors was 3.5 years (mean 4.5 3.1 years); 25%were followed at least
5.9 years, and 10% were followed at least 8.8 years.
Data Analysis
Survival after transplant. Survival was estimated nonparametri-
cally by the Kaplan–Meier method and parametrically by hazard function
methodology.13 Bagging was used to identify reliable risk factors from
among those listed in Appendix B on the basis of 1000 bootstrap samplesThe Journal of Thoracic and Caand automated stepwise selection, with a variable-retention criterion of
P  .05.14 Then, the factor of interest, pTLCRatio or aTLCRatio, was entered
into the model to analyze its effect. In the multivariable analysis, sporadic
missing values for variables were imputed with the mean value.
Spirometry after transplant. Repeated measurements of FEV1%
were analyzed longitudinally across time for temporal trends after transplan-
tation. A nonlinear mixed model with decomposition of time phases was
used to model the temporal trend. A temporal trend was separately identified
for the 3 largest diagnostic groups: emphysema, bronchiectasis, and IPF. To
assess the effect of pTLCRatio and aTLCRatio, the rate was incorporated first
into a model with only double versus single lung transplantation and then
into a model containing other patient factors previously found to affect post-
operative spirometry values.15
Missing data. Data fields missing more than 30% of values were ex-
cluded from the analysis, except pulmonary artery pressures and 6-minute
TABLE 1. Recipient, donor, and transplant details (total n ¼ 469)
Variable n* No. (%) or Mean ± SD
Recipient
Demography
Female 469 232 (49)
Age at transplant (y) 469 48  12
Body mass index (kg/m2) 468 24  5.3
Diagnosis
Emphysema 469 228 (49)
Bronchiectasis 469 88 (19)
IPF 469 81 (17)
PAH 469 29 (6.2)
Pulmonary function
FEV1 (% of predicted)y 345 28  16
FVC (% of predicted)y 345 50  16
FEV1/FVCy 345 0.6  0.36
Pulmonary diffusing capacity 200 28  4.02
Immunology
PRA>10% 467 18 (3.9)
Hemodynamics
6-min walk (ft) 203 1150  276
PA systolic pressure (mm Hg) 294 43  20
PA diastolic pressure (mm Hg) 293 21  11
PA mean pressure (mm Hg) 276 29  14
Central venous pressure (mm Hg) 219 7.6  4.8
Cardiac index (L/min/m2) 259 2.9  0.79
Wedge pressure (mm Hg) 234 12  6.0
Donor
Demography
Female 467 234 (50)
Pediatric donor age<18 y 464 56 (12)
Age at transplant (y) 464 36  15
Comorbidity
Smoking 116 62 (53)
Cause of death
Head trauma 469 197 (42)
Transplant
Double lung 469 197 (42)
Maximum ischemic time (min) 395 224  70
FEV1, Forced expiratory volume in 1 second; FVC, forced vital capacity; IPF, idio-
pathic pulmonary fibrosis; PA, pulmonary artery; PAH, pulmonary arterial hyperten-
sion; PRA, panel reactive antibody; SD, standard deviation. *Number of patients
with data available. yNational Health and Nutrition Examination Survey normalized.rdiovascular Surgery c Volume 137, Number 5 1235
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patients were sometimes unable to breathhold, aTLC was unmeasured.
Therefore, multiple imputation was used in multivariable analyses to max-
imize the number of patients available in each analysis. Bootstrapping was
FIGURE 1. Distribution of differences in aTLC versus pTLC by diagno-
sis. PAH, Pulmonary arterial hypertension; IPF, idiopathic pulmonary fibro-
sis; aTLC, actual total lung capacity; pTLC, predicted total lung capacity.
TABLE 2. Estimated donor-to-recipient total lung capacity by
diagnosis
Diagnosis No. Mean ± SD Range
pTLCRatio
Emphysema 226 1.01  0.14 0.56–1.59
Bronchiectasis 86 1.01  0.13 0.59–1.27
PAH 28 1.06  0.19 0.72–1.53
IPF 80 0.95  0.14 0.55–1.25
Other 42 0.98  0.19 0.56–1.56
aTLCRatio
Emphysema 152 0.84  0.17 0.52–1.41
Bronchiectasis 52 1.13  0.35 0.62–2.24
PAH 13 1.23  0.27 0.84–1.77
IPF 57 1.93  0.70 0.73–4.20
Other 29 1.53  0.69 0.64–2.97
aTLCRatio, Donor-to-recipient actual total lung capacity ratio; IPF, idiopathic pulmo-
nary fibrosis; PAH, pulmonary arterial hypertension; pTLCRatio, donor-to-recipient
predicted total lung capacity ratio; SD, standard deviation.1236 The Journal of Thoracic and Cardiovascular Superformed on the first imputation, and the final model underwent 5 imputa-
tion cycles before aggregating results.
Data presentation. Continuous variables are summarized by mean
standard deviation, and categoric variables are summarized by frequencies
and percentages. All analyses were performed with SAS statistical software
(SAS v9.1; SAS Inc, Cary, NC).
RESULTS
Effect of Donor Lung Size on Survival
Unadjusted survival at 6 months and 1, 3, and 5 years was
87%, 79%, 62%, and 45%, respectively. The hazard func-
tion resolved into 2 phases; 47 deaths occurred in the early
phase, and 207 deaths occurred in the longer late phase. In
multivariable analysis, pTLCRatio did not reliably predict
overall survival (Figure 3) or survival when analyzed for
each separate disease diagnosis (Table 3). aTLCRatio also
was not associated with overall survival. However, when
the 3 most common disease diagnoses were analyzed sepa-
rately, only patients with emphysema receiving lungs from
donors at either extreme of lung size (aTLCRatio < 0.67
and>1.03, representing the top and bottom 15% of values)
FIGURE 2. Cumulative distribution of donor-to-recipient TLC according
to diagnosis. A, Donor-to-recipient pTLCRatio. B, Donor-to-recipient
aTLCRatio. IPF, Idiopathic pulmonary fibrosis; pTLCRatio, donor-to-
recipient predicted total lung capacity ratio; aTLCRatio, donor-to-recipient
actual total lung capacity ratio.rgery c May 2009
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1.03 (Figure 4).
Effect of Donor Lung Size on Spirometry
The temporal trend of FEV1% after transplantation dem-
onstrated an early peaking phase followed by a slowly rising
late phase. FEV1% remained relatively constant thereafter,
with some slow decline over time.
Neither pTLCRatio nor aTLCRatio had an overall effect on
postoperative FEV1%. However, when analyzed by specific
TABLE 3. Risk factors for mortality




Higher PA diastolic pressurey 0.11  0.03 .002 63
Earlier date of operation 0.25  0.06 <.0001 93
Late hazard phase
PRA>10 % 0.98  0.32 .002 73
Recipient blood type A 0.30  0.15 .04 52
CPB not used 0.45  0.21 .03 53
pTLCRatioz 1.50  1.37 .3 11
Emphysema 1.86  1.60 .3 22
IPF 2.62  1.87 .2 22
Bronchiectasis 2.12  1.65 .2 22
Interaction: emphysema
$ TLCRatioz
1.19  1.50 .4 22
Interaction: IPF $ pTLCRatioz 1.92  1.73 .3 23
Interaction: bronchiectasis
$ pTLCRatioz
1.27  1.55 .4 53
CPB, Cardiopulmonary bypass; IPF, idiopathic pulmonary fibrosis; PA, pulmonary ar-
tery; PRA, panel reactive antibody; pTLCRatio, donor-to-recipient predicted total lung
capacity ratio; SE, standard error. *Percent of times factor appeared in 500 bootstrap
models. y(PA diastolic pressure/25)2, squared transformation. z(1/pTLCRatio), inverse
transformation.
FIGURE 3. Overall unadjusted survival by terciles of donor-to-recipient
pTLCRatio. Symbols represent deaths. Vertical bars represent 68% confi-
dence limits equivalent to  1 standard error. Numbers in parentheses rep-
resent patients remaining at risk (P [log-rank] ¼ .4). o ¼ patients with
largest 15% of pTLCRatio.  ¼ patients with the middle 70% of pTLCRatio.
, ¼ patients with the smallest 15% of pTLCRatio.The Journal of Thoracic and Cdisease diagnoses (Table 4), 1) a larger pTLCRatio and
smaller aTLCRatio predicted a slightly higher FEV1% early
after transplantation for emphysema, but had no late effect
(Figure 5, A and B); 2) a smaller pTLCRatio and smaller
aTLCRatio predicted higher FEV1% in the late phase after
transplantation for IPF (Figure 6, A and B); and 3) a larger
pTLCRatio predicted higher FEV1% in the early phase but
lower FEV1% in the late phase in patients undergoing trans-
plantation for bronchiectasis, and a smaller aTLCRatio pre-
dicted higher FEV1% in the late phase (Figure 7, A and B).
DISCUSSION
Effect of Donor Size on Survival
The Cleveland Clinic sizing strategy is universal across
diseases and factors in 2 sequential components related to
TLC when sizing donor to recipient. The first component at-
tempts to closely match pTLC of donor and recipient. Al-
though this was achieved, a few patients in all disease
categories received lungs that were markedly oversized
and undersized, as shown by the wide range of pTLCRatio.
However, there was minimal survival impact of pTLCRatio,
suggesting that wider size discrepancies can be accepted.
The second aspect of the sizing strategy comes into play
when exact matching by pTLCRatio is not possible. Donor
size is then targeted to achieve a pTLCD that is between
aTLCR and pTLCR. This approach factors in disease-spe-
cific chest remodeling. Interestingly, the aTLCRatio was
found to have no effect overall on survival. However,
when considered according to underlying disease, patients
with emphysema who received organs at the extremes of
aTLCRatio had worse survival: aTLC is larger than pTLC
in patients with emphysema.16 When selecting an allograft
for a patient with emphysema, lung size should be smaller
than aTLC to improve respiratory mechanics, similar to
FIGURE 4. Unadjusted survival in patients with emphysema stratified by
donor-to-recipient aTLCRatio. o¼ patients with extreme values of aTLCRatio
(n¼ 44).,¼ the 70% of patients with more typical values (n¼ 108). For-
mat is as in Figure 3. P (Wilcoxon) ¼ .01.ardiovascular Surgery c Volume 137, Number 5 1237
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factors,* according to diagnosis
pTLCRatio aTLCRatio
Diagnosis Risk factor Estimate ± SE P Estimate ± SE P
Emphysema Early phase 0.12  0.06y .03 0.11  0.05y .02
Late phase 0.02  0.06y .7 1.16  0.46y .012
IPF Early phase 0.14  0.12y .3 0.11  0.11z .3
Late phase 0.44  0.14y .003 0.58  0.16z .0005
Bronchiectasis Early phase 3.86  0.64 <.0001 0.02  0.06 .7
Late phase 0.85  0.36 .02 0.36  0.07 <.0001
aTLCRatio, Donor-to-recipient actual total lung capacity ratio; IPF, idiopathic pulmonary fibrosis; pTLCRatio, donor-to-recipient predicted total lung capacity ratio; SE, standard
error. *Other patient factors include age, ratio of donor to recipient age, double lung transplant, blood type A, and creatinine. yExponential transformation, eðTLCRatioÞ. zNatural
log transformation, Ln(TLCRatio).what is achieved with lung volume reduction surgery.17-19
Transplanting a lung that is so large that it approximates
the size of the hyperinflated lung likely produces inefficient
respiratory mechanics and contributes to diminished long-
term survival.4 Downsizing of donor lungs has been de-
scribed for smaller recipients.20,21 However, the amount of1238 The Journal of Thoracic and Cardiovascular Susize mismatch that mandates downsizing and the amount
of size reduction that should be performed are not clear.
For this reason, downsizing has not been practiced at Cleve-
land Clinic. Our data suggest that wide discrepancies in size
matching can be accepted without downsizing and that this
practice should be rare. However, a patient with emphysemaFIGURE 5. Predicted mean FEV1% after lung transplantation for emphy-
sema from multivariable model of Table 4. A, Individual curves represent
specific values of donor-to-recipient pTLCRatio. B, Individual curves repre-
sent specific values of donor-to-recipient aTLCRatio. FEV1%, Forced expi-
ratory volume in 1 second; pTLCRatio, donor-to-recipient predicted total
lung capacity ratio; aTLCRatio, donor-to-recipient actual total lung capacity
ratio.FIGURE 6. Predicted mean FEV1% after lung transplantation for IPF
from multivariable model of Table 4. A, Individual curves represent specific
values of donor-to-recipient pTLCRatio. B, Individual curves represent
specific values of donor-to-recipient aTLCRatio. FEV1%, Forced expiratory
volume in 1 second; pTLCRatio, donor-to-recipient predicted total lung
capacity ratio; aTLCRatio, donor-to-recipient actual total lung capacity
ratio.rgery c May 2009
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than the aTLC).
At the other extreme, mechanisms of chest remodeling for
an undersized allograft, such as diaphragmatic elevation, al-
terations in the bony thorax, and mediastinal shift, may have
a maximal range of compensation.18 At this point, residual
space problems, such as persistent pneumothorax, intracta-
ble pleural effusions, and empyema, may negatively affect
survival.22-24
Effect of Donor Size on Spirometry
Neither pTLCRatio nor aTLCRatio affected overall postop-
erative FEV1%, supporting previous findings that donor
lung size has minimal effect on lung function after transplan-
tation.1,8,25 However, there were disease-specific differ-
ences. For emphysema, early effects favored a larger
FIGURE 7. Predicted mean FEV1% after lung transplantation for bron-
chiectasis from multivariable model of Table 4. A, Individual curves repre-
sent specific values of donor-to-recipient pTLCRatio. B, Individual curves
represent specific values of donor-to-recipient aTLCRatio. FEV1%, Forced
expiratory volume in 1 second; pTLCRatio, donor-to-recipient predicted total
lung capacity ratio; aTLCRatio, donor-to-recipient actual total lung capacity
ratio.The Journal of Thoracic and CpTLCRatio, but long-term spirometry was minimally af-
fected. For IPF, a smaller pTLCRatio produced better long-
term spirometry, and for bronchiectasis, a larger pTLCRatio
predicted better early spirometry but worse late spirometry.
Similar trends were noted for the aTLCRatio. Although statis-
tically significant, it seems unlikely that the small differ-
ences in spirometry within differing donor-to-recipient size
ratios are clinically important.
Limitations
The primary limitation of this study is its retrospective na-
ture. In addition, the mechanisms behind the findings can
only be postulated. End points were limited to survival
and spirometry. Finally, the sizing strategy used during the
time frame of this study focused on minimizing size mis-
match and was not designed to address extremes of tolerable
size discrepancy. Exceptions made to the standard sizing
strategy that resulted in mismatch extremes were surgeon
specific, and the rationale was impossible to ascertain retro-
spectively.
CONCLUSIONS
Transplant surgeons turn down organs that are believed to
be too large or too small for a recipient. Some even ‘‘down-
size’’ lungs that they believe are too large in an effort to
increase organ use.1-3,26 It is not clear when this is necessary
or to what extent this strategy is helpful, and underlying
disease diagnosis compounds the uncertainty.10 Should a do-
nor lung be selected that is similar in size to the diseased
lung or more closely approximates the nondiseased condi-
tion? The sizing strategy that has been analyzed considers
these factors and seems effective. The results suggest that
wide size discrepancies can be accepted without adverse ef-
fect, which may improve a patient’s odds of undergoing
transplantation.
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tion. Transplant Proc. 2005;37:1526-9.Appendix A. Formulae for calculating predicted total lung capacity
Male patients aged<18 y
(38.1842 $ age þ 23.0973 $ height þ 44.5411 $ weight
2236.7774) O 1000
Female patients aged<18 y
(13.0601 $ age þ 40.4346 $ height þ 14.526 $ weight
3495.2291) O 1000
Male patients aged>18 y
0.08 $ heightþ0.003 $ age7.333
Female patients aged>18 y
0.059 $ height4.537Appendix B. Variables used in multivariable analysis
Recipient
Demography: Female, Caucasian, African-American,
age, body mass index, body surface area, weight $ height
Diagnosis: Idiopathic pulmonary fibrosis, emphysema,
bronchiectasis
Comorbidity: Diabetes, hypertension, creatinine
Pulmonary function: FEV1%, NHANES normalized;
FVC%, NHANES normalized; FEV1%/FVC% ratio, actual
total lung capacity, predicted total lung capacity, donor-
to-recipient actual total lung capacity ratio, donor-to-recipient
predicted total lung capacity ratio
Serology/immunology: Blood type A, blood type AB,
blood type B, blood type O, Rhþ, panel reactive antibody
>10%, CMV serology
Hemodynamics: 6-minute walk, systolic blood pressure,
diastolic blood pressure, mean blood pressure, pulmonary
artery systolic pressure, pulmonary artery diastolic pressure,
pulmonary artery mean pressure
Donor
Demography: Female, Caucasian, African-American,
pediatric donor, age at transplant, body mass index, body
surface area, weight $ height
Comorbidity: History of hypertension, creatinine
Pulmonary function: Estimated total lung capacity
Serology/immunology: Blood type A, blood type B,
blood type O, Rhþ, CMV
Cause of death: Anoxia, cerebral bleeding, stroke, head
trauma
Mechanism of death: Blunt injury, gunshot wound, ische-
mic/stroke
Transplant
Procedure: Double lung transplantation, right lung trans-
plantation only, left lung transplantation only, cardiopulmo-
nary bypass, time from January 1, 1990, to index operation,
maximum ischemic time
Donor–recipient mismatch: Donor male and recipient
male; donor female and recipient female; donor male and
recipient female; donor female and recipient male; CMV:
donor–recipient mismatch; RH: donor–recipient mismatch;
ratio of donor-to-recipient age
FEV1%, Forced expiratory volume in 1 second; FVC%,
forced vital capacity; NHANES, National Health and Nutri-
tion Examination Survey; CMV, cytomegalovirus.rgery c May 2009
Mason et al Cardiothoracic TransplantationFIGURE E1. Number of patients with spirometry measurements available
at and beyond various time points, and number of spirometry measurements
available for analysis (black bars, spirometry measurements; grey bars,
patients).The Journal of Thoracic and Cardiovascular Surgery c Volume 137, Number 5 1240.e1
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